Top

Published in:

Open Access 01-12-2018 | Research

Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung

Authors: Eisuke Mochizuki, Shun Matsuura, Kyohei Oishi, Koichi Miyashita, Koshiro Ichijyo, Syunya Furukawa, Miyuki Nagaoka, Shinichiro Mikura, Masaru Tsukui, Naoki Koshimizu, Shogo Sakurai, Kazuhiro Asada, Toshihiro Shirai

Published in: World Journal of Surgical Oncology | Issue 1/2018

Abstract

Background

There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma.

Methods

Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis.

Results

Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS.

Conclusion

Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed

Niiranen A, et al. Long-term survival in small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1988;24(4):749–52.CrossRefPubMed

Namikawa S, Den T, Kimura M, et al. The role of surgical resection and the effects of neo-adjuvant therapy in the management of small cell lung cancer. Surg Today. 1994;24(4):342–6.CrossRefPubMed

Paci M, Cavazza A, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg. 2004;77:1163–7.CrossRefPubMed

Sunaga N, Tsuchiya S, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology. 1999;57(2):143.CrossRefPubMed

Okada M, Nishio W, Sakamoto T, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg. 2004;78:1004–9.CrossRefPubMed

Kinoshita T, Ohtsuka T, et al. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Oncol. 2015;10:619–28.CrossRefPubMed

Ginsberg RJ, Rubinstein LV, et al. Randomized trial of lobectomy versus limited resection for T1 N0 non-small lung cancer. Ann Thorac Surg. 1995;60(3):615–22.CrossRefPubMed

Allen MS, Darling GE, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81(3):1013–9.CrossRefPubMed

10.

Darling GE, Allen MS, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: result of the American College of surgery Oncology group Z0030 trial. J Thorac Cardiovasc Surg. 2011;141(3):662–70.

11.

Weksler B, Nason KS, et al. Surgical resection should be considered for stage I and II small cell carcinoma of the lung. Ann Thorac Surg. 2012;94(3):889–93.CrossRefPubMed

12.

Buccheri G, Ferrigno D, et al. Lung cancer: clinical presentation and specialist referral time. Eur Respir J. 2004;24(6):898–904.CrossRefPubMed

Title: Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
Authors: Eisuke Mochizuki
Shun Matsuura
Kyohei Oishi
Koichi Miyashita
Koshiro Ichijyo
Syunya Furukawa
Miyuki Nagaoka
Shinichiro Mikura
Masaru Tsukui
Naoki Koshimizu
Shogo Sakurai
Kazuhiro Asada
Toshihiro Shirai
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-018-1337-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature

Laparoscopic and endoscopic cooperative surgery for intra-mucosal gastric carcinoma adjacent to the ulcer scars

Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study

Need for normalization: the non-standard reference standard for microvascular invasion diagnosis in hepatocellular carcinoma

Mediastinoscopy-assisted esophagectomy for T2 middle and lower thoracic esophageal squamous cell carcinoma patients

Pancreaticojejunostomy with or without reinforcement after pancreaticoduodenectomy: surgical technique of ligamentum teres hepatis wrap around pancreaticojejunostomy